LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Akcijų sąrašas・United Therapeutics Corp

United Therapeutics Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

545.69 -0.3

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

543.27

Max

551.34

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-89M 275M
Pardavimai	-8.7M 782M
P/E Sektoriaus vid.	20.134 49.888
Pelnas, tenkantis vienai akcijai	5.82
Pelno marža	35.176
Darbuotojai	1,400
EBITDA	-176M 348M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+21.1% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.5B 23B
Ankstesnė atidarymo kaina	545.99
Ankstesnė uždarymo kaina	545.69

Naujienos nuotaikos

By Acuity

50%

161 / 344 reitingas Healthcare

United Therapeutics Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-08 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

2026-06-08 15:41; UTC

Pagrindinės rinkos jėgos

American Battery Shares Jump on Energy Department Victory

2026-06-08 23:46; UTC

Rinkos pokalbiai

Nikkei May Rebound After Monday's Selloff -- Market Talk

2026-06-08 23:37; UTC

Rinkos pokalbiai

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

2026-06-08 23:25; UTC

Rinkos pokalbiai

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

2026-06-08 23:25; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-08 21:57; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

2026-06-08 21:56; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce Agrees to Buy m3ter

2026-06-08 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-08 19:22; UTC

Rinkos pokalbiai

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

2026-06-08 19:01; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

2026-06-08 18:52; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-06-08 18:52; UTC

Rinkos pokalbiai

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

2026-06-08 18:17; UTC

Rinkos pokalbiai

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

2026-06-08 17:32; UTC

Rinkos pokalbiai

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

2026-06-08 17:29; UTC

Rinkos pokalbiai

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

2026-06-08 17:29; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-08 16:55; UTC

Įsigijimai, susijungimai, perėmimai

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

2026-06-08 16:54; UTC

Įsigijimai, susijungimai, perėmimai

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

2026-06-08 16:40; UTC

Rinkos pokalbiai

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

2026-06-08 16:31; UTC

Rinkos pokalbiai

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

2026-06-08 16:27; UTC

Rinkos pokalbiai

Mexican Inflation Seen Easing in May -- Market Talk

2026-06-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-08 16:03; UTC

Įsigijimai, susijungimai, perėmimai

Orange Bought Stake From Lorca

2026-06-08 16:01; UTC

Įsigijimai, susijungimai, perėmimai

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

2026-06-08 16:01; UTC

Įsigijimai, susijungimai, perėmimai

Orange Acquires 100% Ownership of MasOrange

2026-06-08 15:58; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-08 15:58; UTC

Rinkos pokalbiai

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

2026-06-08 15:55; UTC

Rinkos pokalbiai

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

2026-06-08 15:41; UTC

Rinkos pokalbiai

Gold Falls Below 200-Day Moving Average -- Market Talk

Akcijų palyginimas

Kainos pokytis

United Therapeutics Corp Prognozė

Kainos tikslas

By TipRanks

21.1% į viršų

12 mėnesių prognozė

Vidutinis 665.9 USD 21.1%

Aukščiausias 738 USD

Žemiausias 516 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines United Therapeutics Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių United Therapeutics Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

161 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.